Bausch + Lomb Corporation Common Shares (BLCO)

Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and investors should exercise caution as some have shaky business models.

The company’s Solta segment, which includes medical aesthetics, saw Q4 revenue climb 34% to $138 million, fueled by strong demand in South Korea and China.

Medical device company Globus Medical (NYSEGMED) will be announcing earnings results tomorrow after the bell. Here’s what to expect.

Medical technology company Integer Holdings (NYSEITGR) will be announcing earnings results tomorrow before market hours. Here’s what you need to know.

Eyecare company Bausch + Lomb (NYSEBLCO) reported revenue ahead of Wall Street’s expectations in Q4 CY2024, with sales up 9.1% year on year to $1.28 billion. On the other hand, the company’s full-year revenue guidance of $4.98 billion at the midpoint came in 1.1% below analysts’ estimates. Its non-GAAP profit of $0.25 per share was 6.9% above analysts’ consensus estimates.

The highly indebted healthcare stock rose on rumors it may be selling itself.

Eyecare company Bausch + Lomb (NYSEBLCO) will be announcing earnings results tomorrow morning. Here’s what to expect.

Bausch + Lomb's efforts to sell have so far been unsuccessful. Meanwhile, KKR is aggressively pursuing a deal for Fuji Soft.

Dental supply maker Patterson Companies Inc announced Thursday that it is exploring strategic options, including a sale or merger, to boost shareholder value.

IMG tennis assets are on the auction block. The announcement came after TKO inked a deal with Endeavor for Professional Bull Riders.

S&P Global's Joe Mantone puts the latest M&A data in perspective and how deal pros might react post-Election Day.

It was quite a busy and eventful day for the company.

Private equity giants TPG and Blackstone are pursuing a potential $14 billion buyout of Bausch + Lomb.

Federal Reserve's rate cut boosted tech, construction, industrial, machinery, and financial sectors. Top-performing mid-cap stocks last week.

Bausch + Lomb is exploring a sale as its parent company, Bausch Health, faces significant debt and creditors' opposition to a spin-off.

Bausch + Lomb is reportedly considering a sale. But its potential acquirers could come up against antitrust concerns.

Tech stocks soared to their best session in five months on Wednesday, ahead of the highly anticipated Federal Open Market Committee (FOMC) meeting.